A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Nilsson, S; Strang, P; K Aksnes, A; Franzèn, L; Olivier, P; Pecking, A; Staffurth, J; Vasanthan, S; Andersson, C; S Bruland, Ø

doi:10.1016/j.ejca.2011.12.023

Public

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Shared by NobleBlocks on Mar 1, 2012 • 12:00 AM UTC

Authors:

S Nilsson

P Strang

A K Aksnes

Abstract

PURPOSE: To investigate the dose-response relationship and pain-relieving effect of radium-223, a highly bone-targeted alpha-pharmaceutical. METHODS: One hundred patients with castration-resistant prostate cancer (CRPC) and painful bone metastases were randomized to a single intravenous dose of 5, 2...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!